

DECISION OF THE EEA JOINT COMMITTEE
No 107/2021

of 19 March 2021

**amending Annex II (Technical regulations, standards, testing and certification) to the
EEA Agreement**

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof,

Whereas:

- (1) Commission Delegated Regulation (EU) 2020/1431 of 14 July 2020 amending Regulation (EU) No 658/2014 of the European Parliament and of the Council as regards the adjustment to the inflation rate of the amounts of the fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use¹ is to be incorporated into the EEA Agreement.
- (2) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

The following indent is added in point 16 (Regulation (EU) No 658/2014 of the European Parliament and of the Council) of Chapter XIII of Annex II to the EEA Agreement:

- ‘- **32020 R 1431:** Commission Delegated Regulation (EU) 2020/1431 of 14 July 2020 (OJ L 331, 12.10.2020, p. 2).’

Article 2

The text of Delegated Regulation (EU) 2020/1431 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the *Official Journal of the European Union*, shall be authentic.

Article 3

This Decision shall enter into force on 20 March 2021, provided that all the notifications under Article 103(1) of the EEA Agreement have been made*.

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the *Official Journal of the European Union*.

¹ OJ L 331, 12.10.2020, p. 2.

* No constitutional requirements indicated.

Done at Brussels, 19 March 2021.

*For the EEA Joint Committee
The President*

Clara Ganslandt

*The Secretaries
To the EEA Joint Committee*

Hege M. Hoff

Mikołaj Karłowski

Not yet published